Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases
Summary
A clinical trial led by Cedars-Sinai Medical Center found that a new drug combination can lower the risk of death by about 40% in patients with aggressive prostate cancer. The treatment combines the drug enzalutamide with a hormone therapy called leuprolide. Results were presented at a medical conference in Berlin, involving over 1,000 patients across 17 countries.Key Facts
- A new drug combo helps reduce deaths in aggressive prostate cancer by about 40%.
- The treatment pairs enzalutamide, a drug currently used for some prostate cancers, with leuprolide, a hormone therapy.
- The trial involved more than 1,000 patients from 244 sites in 17 countries.
- Participants had prostate cancer that returned after surgery or radiation.
- Enzalutamide is FDA-approved and follows national cancer treatment guidelines.
- The trial observed a significant survival improvement over eight years with the drug combination.
- The research was presented at the European Society for Medical Oncology Congress in Berlin.
- Prostate cancer is one of the most common cancers among U.S. men, second only to skin cancer.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.